Viagra may heal a previously untreatable disorder known as Leigh syndrome

The drug was never meant for this.

It was designed, refined, marketed, and joked about for an entirely different purpose; its name turned into shorthand for a certain kind of late-night television humor.

But inside clinics and laboratories, far from the advertisements and the punchlines, physicians have begun to notice something they were not supposed to see.

A signal.

In a small, tightly controlled study reported in Nature, researchers found that sildenafil—the drug widely sold as Viagra—may improve symptoms in patients with Leigh syndrome, a rare and often fatal mitochondrial disorder that has, until now, offered families little more than prognosis and grief.

Six patients were treated. That number is too small to inspire confidence, too large to ignore. Their ages ranged from nine months to 38 years, spanning the full arc of a disease that typically announces itself early and moves quickly.

Leigh syndrome affects roughly one in 40,000 newborns. It disrupts the mitochondria—the structures inside cells responsible for producing energy—turning the most basic biological process into a slow collapse.

Children lose skills they had just begun to acquire. Muscles weaken. Breathing becomes uncertain. Many die before the age of three, often from sudden respiratory failure that arrives without warning and leaves no time for intervention.

“Leigh syndrome is a severe, rare genetic neurometabolic disorder typically appearing in the first year of life, characterized by progressive loss of mental and movement abilities due to impaired mitochondrial energy production,” according to the National Library of Medicine. “It causes symptoms like developmental regression, hypotonia, and breathing issues, often leading to death within a few years, frequently by age 2–3, usually due to respiratory failure.”

There has been no standard treatment. No reliable therapy. No approved drug that changes the course of the disease.

Until now, the most honest answer doctors could give was that nothing worked.

The study did not begin with sildenafil. It began with a kind of scientific exhaustion—the recognition that designing a new drug from scratch would take years most patients do not have. So researchers turned to what already existed. Using stem cells derived from patients with Leigh syndrome, teams in the United States and Europe screened approximately 5,600 existing compounds, searching for any measurable effect on mitochondrial function.

This is what modern medicine does when it runs out of options. It starts over by looking backward.

Sildenafil emerged not as a miracle but as a possibility. Its known mechanism—improving blood flow through the modulation of nitric oxide signaling—did not obviously promise to fix mitochondrial dysfunction. But in the laboratory, it appeared to do something. Not everything, not enough, but something.

That was sufficient to proceed.

The six patients who received the drug were not identical cases, and their outcomes were not identical either. But most showed measurable improvement. Some gained mobility. Others demonstrated increased muscle strength. Several were better able to breathe independently, a change that, in this disease, can mean the difference between life and its abrupt end.

The improvements were not described as cures. No one involved in the study is making that claim. The disease remains. The underlying genetic defects are still present. What has changed, if the findings hold, is the trajectory.

It may no longer be fixed.

The implications are as unsettling as they are hopeful. A drug long associated with one of the most commercialized conditions in modern medicine may now occupy a place in the treatment of one of its most neglected. It is not an elegant solution. It is not even, yet, a proven one. The study is small, lacks a placebo control, and demands replication in larger, more rigorous trials.

But it breaks something open.

For decades, rare diseases like Leigh syndrome have existed at the margins of pharmaceutical development, too uncommon to attract sustained investment, too complex to yield easy answers. Families have relied on experimental protocols, off-label treatments, and the thin hope that research might catch up in time.

Drug repurposing—taking an existing medication and applying it to a new condition—has always been an appealing shortcut, but it rarely produces results that matter. Most candidates fail quietly. Most signals dissolve under closer scrutiny.

This one has not, at least not yet.

What makes the findings difficult to dismiss is not their scale but their consistency. Across patients with different ages and disease progression, the pattern of improvement appears in forms that clinicians recognize: stronger muscles, steadier breathing, regained function. These are not abstract endpoints. They are the things families measure in minutes and movements, in the difference between dependence and a brief, fragile independence.

Still, caution is not optional. Early-stage results have misled medicine before. What looks like progress in six patients can disappear in sixty. The placebo effect, the natural variability of disease, the biases inherent in small studies—all remain present.

The researchers acknowledge this. They call for larger trials, randomized designs, and a more disciplined evaluation of what sildenafil can and cannot do in this context.

But the existence of the signal changes the conversation.

For a condition that offered no treatment, there is now a candidate. For patients who faced a disease defined by decline, there is now the possibility—however provisional—of interruption.

It is not a breakthrough in the cinematic sense. There are no declarations of victory, no promises of imminent cures. There is only a shift, subtle but unmistakable, in what can be said with honesty.

Before, there was nothing.

Now, there is something that might work.